Barrington Research Maintains Outperform on Haemonetics, Maintains $105 Price Target
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Michael Petusky has maintained an Outperform rating on Haemonetics (NYSE:HAE), with a price target of $105.
April 12, 2024 | 2:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barrington Research maintains an Outperform rating on Haemonetics with a $105 price target.
The reaffirmation of an Outperform rating and a $105 price target by Barrington Research suggests a positive outlook on Haemonetics' stock, likely due to the company's strong fundamentals or growth prospects. This could lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100